Skip to main content
. 2005 Mar 22;92(7):1231–1239. doi: 10.1038/sj.bjc.6602481

Figure 2.

Figure 2

Overall survival of patients with stage II–III NSCLCs in relation to biological markers. (A) Ki-67 index, (B) tumour vascularity, (C) TS status, (D) TS status and UFT-based chemotherapy, (E) VEGF-A status, (F) VEGF-C status, and (G) E-cadherin status.